Lakefront Biotherapeutics Advances Gamgertamig After Ouro Deal
MECHELEN, Belgium, August 10, 2026 Lakefront Biotherapeutics NV reported its half-year 2026 financial results and provided a business update...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
MECHELEN, Belgium, August 10, 2026 Lakefront Biotherapeutics NV reported its half-year 2026 financial results and provided a business update...
FREMONT, California, August 10, 2026 Alamar Biosciences, Inc. announced an expansion of its strategic partnership with the Alzheimer’s Disease...
